Amgen Reports Initiation of Second P-III METEORIC-HF Study of Omecamtiv Mecarbil for Patients with Heart Failure

 Amgen Reports Initiation of Second P-III METEORIC-HF Study of Omecamtiv Mecarbil for Patients with Heart Failure

Amgen Reports Initiation of Second P-III METEORIC-HF Study of Omecamtiv Mecarbil for Patients with Heart Failure

Shots:

  • The P-III METEORIC-HF study involves assessing of omecamtiv mecarbil (25/50 mg, bid) vs PBO in 270 patients in the ratio (2:1) on exercise capacity as determined by cardiopulmonary exercise testing (CPET) with HFrEF at sites throughout the US, Canada and EU
  • In 2006, Amgen & Cytokinetics collaborated to develop therapeutics for the activation of cardiac sarcomere for heart failure. The second P-III METEORIC-HF Study is conducted by Cytokinetics in collaboration with Amgen and to be fund by Servier
  • Omecamtiv Mecarbil is a cardiac muscle activator evaluated in global P-III GALACTIC-HF study versus PBO for patients with heart failure or have had a hospitalization or admission to an emergency room for heart failure within one year prior to screening

Click here to read full press release/ article | Ref: Amgen | Image: Twitter


Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post